Journal Article

Posttransplantation Lymphoproliferative Disorder Associated with OKT3 and Decreased Antiviral Prophylaxis in Pancreas Transplant Recipients

Susan Keay, David Oldach, Ann Wiland, David Klassen, Eugene Schweitzer, Lynne V. Abruzzo, Dhruv Kumar and Stephen Bartlett

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 26, issue 3, pages 596-600
Published in print March 1998 | ISSN: 1058-4838
Published online March 1998 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/514579
Posttransplantation Lymphoproliferative Disorder Associated with OKT3 and Decreased Antiviral Prophylaxis in Pancreas Transplant Recipients

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Between September 1994 and October 1995, we diagnosed and treated four cases of early onset posttransplantation lymphoproliferative disorder (PTLD) occurring within 62 days of pancreas transplantation. The development of PTLD was associated with both a significantly higher total muromonab-CD3 (OKT3) dose and a lack of ganciclovir/acyclovir prophylaxis, but it was not associated with the total dose of antithymocyte globulin or cytomegalovirus serostatus. All four patients were treated aggressively and survived without evidence of recurrent PTLD more than 1.5 years later. We conclude that the use of a high total dose of OKT3 puts pancreas transplant recipients at increased risk for early onset PTLD, while ganciclovir/acyclovir prophylaxis may help to prevent this disorder; however, if early onset PTLD does occur in these patients, aggressive therapy can lead to a favorable outcome.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.